What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...
Medical device company Globus Medical (NYSE:GMED) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 25.7% year on year to $826.4 million. The company’s full-year revenue guidance of $3.2 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.28 per share was 11% above analysts’ consensus estimates.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
What a fantastic six months it’s been for Globus Medical. Shares of the company have skyrocketed 62.5%, hitting $87.15. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
